PE20080345A1 - Derivados de piperazina como agonistas del receptor de gpr38 - Google Patents
Derivados de piperazina como agonistas del receptor de gpr38Info
- Publication number
- PE20080345A1 PE20080345A1 PE2007000819A PE2007000819A PE20080345A1 PE 20080345 A1 PE20080345 A1 PE 20080345A1 PE 2007000819 A PE2007000819 A PE 2007000819A PE 2007000819 A PE2007000819 A PE 2007000819A PE 20080345 A1 PE20080345 A1 PE 20080345A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- phenyl
- alkyl
- piperazinyl
- agonists
- Prior art date
Links
- 101001132878 Homo sapiens Motilin receptor Proteins 0.000 title abstract 2
- 102100033818 Motilin receptor Human genes 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title abstract 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title 1
- -1 3-FLUOROPHENYL Chemical class 0.000 abstract 3
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 201000006549 dyspepsia Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 208000008384 ileus Diseases 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000010992 reflux Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA I; DONDE A ES FENILO O UN ANILLO HETEROARILO DE 6 MIEMBROS OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALQUILO C1-C4, ALCOXI C1-C4; B ES FENILO OPCIONALMENTE SUSTITUIDO, UN ANILLO HETEROARILO DE 6 MIEMBROS QUE PUEDE CONECTARSE AL CARBONO DE LA AMIDA; Y ES NH, N-ALQUILO C1-C4, O, C=O, CH2; R1 Y R2 SON CADA UNO H, ALQUILO C1-C4; R3 ES FENILO SUSTITUIDO O NO, HETEROARILO, HETEROCICLICO; R4 ES H, ALQUILO C1-C4, ALCOXIALQUILO C1-C4. SON COMPUESTOS PREFERIDOS: 6-(3-FLUOROFENIL)-N-METIL-N-(4-{[(3S)-3-METIL-1-PIPERAZINIL]METIL}FENIL)-3-PIRIDINACARBOXAMIDA, 4'-FLUORO-N-METIL-N-(4-{[(3S)-3-METIL-1-PIPERAZINIL]METIL}FENIL)-4-BIFENILCARBOXAMIDA, N-{4-{[(3R,5S)-3,5-DIMETIL-1-PIPERAZINIL]METIL} FENIL}-6-(4-FLUOROFENIL)-N,2-DIMETIL-3-PIRIDINACARBOXAMIDA, ENTRE OTROS. REFERIDA TAMBIEN A COMPOSICIONES FARMACEUTICAS. DICHOS COMPUESTOS SON AGONISTAS DE GPR38 UTILES EN EL TRATAMIENTO DE REFLUJO GASTROESOFAGICO, DISPEPSIA FUNCIONAL, ESTRENIMIENTO, ILEO PARALITICO, ENTRE OTROS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0612844A GB0612844D0 (en) | 2006-06-28 | 2006-06-28 | Compounds |
| GB0711525A GB0711525D0 (en) | 2007-06-14 | 2007-06-14 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20080345A1 true PE20080345A1 (es) | 2008-05-29 |
Family
ID=38476358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007000819A PE20080345A1 (es) | 2006-06-28 | 2007-06-26 | Derivados de piperazina como agonistas del receptor de gpr38 |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US7700599B2 (es) |
| EP (1) | EP2041093B1 (es) |
| JP (1) | JP5028484B2 (es) |
| KR (1) | KR20090031688A (es) |
| AR (1) | AR061656A1 (es) |
| AT (1) | ATE465150T1 (es) |
| AU (1) | AU2007263712B2 (es) |
| BR (1) | BRPI0713443A2 (es) |
| CA (1) | CA2655540A1 (es) |
| CR (1) | CR10497A (es) |
| CY (1) | CY1110190T1 (es) |
| DE (1) | DE602007006019D1 (es) |
| DK (1) | DK2041093T3 (es) |
| EA (1) | EA015820B1 (es) |
| ES (1) | ES2344484T3 (es) |
| HK (1) | HK1127608A1 (es) |
| HR (1) | HRP20100284T1 (es) |
| IL (1) | IL195900A0 (es) |
| JO (1) | JO2645B1 (es) |
| MA (1) | MA30539B1 (es) |
| MX (1) | MX2009000110A (es) |
| MY (1) | MY147677A (es) |
| NO (1) | NO20090266L (es) |
| NZ (1) | NZ573450A (es) |
| PE (1) | PE20080345A1 (es) |
| PL (1) | PL2041093T3 (es) |
| PT (1) | PT2041093E (es) |
| SI (1) | SI2041093T1 (es) |
| TW (1) | TWI391386B (es) |
| WO (1) | WO2008000729A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0611907D0 (en) | 2006-06-15 | 2006-07-26 | Glaxo Group Ltd | Compounds |
| WO2007012479A2 (en) * | 2005-07-26 | 2007-02-01 | Glaxo Group Limited | Benzylpiperazine derivates and their medical use |
| GB0524814D0 (en) * | 2005-12-05 | 2006-01-11 | Glaxo Group Ltd | Compounds |
| EP2041093B1 (en) * | 2006-06-28 | 2010-04-21 | Glaxo Group Limited | Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases |
| GB0723317D0 (en) * | 2007-11-28 | 2008-01-09 | Glaxo Group Ltd | Compounds |
| CN102317280B (zh) * | 2009-02-27 | 2014-07-23 | 拉夸里亚创药株式会社 | 具有胃动素受体激动活性的羟基吲哚衍生物 |
| US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| EP2531510B1 (en) | 2010-02-01 | 2014-07-23 | Novartis AG | Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists |
| WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
| CN102753527B (zh) | 2010-02-02 | 2014-12-24 | 诺华股份有限公司 | 用作crf受体拮抗剂的环己基酰胺衍生物 |
| RU2013119603A (ru) | 2010-09-27 | 2014-11-10 | Дайити Санкио Компани, Лимитед | Циклогексановое производное |
| US9321727B2 (en) * | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| BR112018015389B1 (pt) | 2016-03-17 | 2023-12-19 | F. Hoffmann-La Roche Ag | Derivado de 5-etil-4-metil-pirazol-3-carboxamida, seu processo de fabricação, preparação farmacêutica oral e uso |
| AU2021350973B2 (en) * | 2020-09-25 | 2024-03-07 | Shanghai Meiyue Biotech Development Co., Ltd. | Pyrimidine carboxamide compound and application thereof |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5385912A (en) * | 1991-03-08 | 1995-01-31 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Multicyclic tertiary amine polyaromatic squalene synthase inhibitors |
| JPH06211886A (ja) | 1992-11-04 | 1994-08-02 | Chugai Pharmaceut Co Ltd | エリスロマイシン誘導体 |
| TW355711B (en) | 1992-11-04 | 1999-04-11 | Chugai Pharmaceutical Co Ltd | Erythromycin derivatives |
| US5593994A (en) * | 1994-09-29 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Prostaglandin synthase inhibitors |
| JP3901239B2 (ja) | 1996-03-13 | 2007-04-04 | 大正製薬株式会社 | アリールアルカン誘導体 |
| US5965578A (en) * | 1996-04-03 | 1999-10-12 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| DE19644195A1 (de) | 1996-10-24 | 1998-04-30 | Solvay Pharm Gmbh | 10,13,15-Trioxatricyclo[9.2.1.1.·9·.·6·]-pentadecanon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US6100239A (en) * | 1996-11-26 | 2000-08-08 | Chugai Seiyaku Kabushiki Kaisha | 13-membered ring macrolide compound, medicine containing the same, and process for producing the same |
| US6060491A (en) * | 1997-06-19 | 2000-05-09 | Dupont Pharmaceuticals | 6-membered aromatics as factor Xa inhibitors |
| US5972939A (en) * | 1997-10-28 | 1999-10-26 | Ortho-Mcneil Pharmaceutical, Inc. | Cyclopentene derivatives useful as antagonists of the motilin receptor |
| US6165985A (en) | 1998-02-13 | 2000-12-26 | Solvay Pharmaceuticals Gmbh | 11-acetyl-12,13-dioxabicyclo[8.2.1]-tridecenone derivatives, processes for their preparation and pharmaceutical compositions comprising them |
| DE19805822B4 (de) | 1998-02-13 | 2009-02-05 | Solvay Pharmaceuticals Gmbh | 11-Acetyl-12,13-dioxabicyclo[8.2.1]tridecenon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| GB9804734D0 (en) * | 1998-03-05 | 1998-04-29 | Pfizer Ltd | Compounds |
| PL215901B1 (pl) * | 1999-04-15 | 2014-02-28 | Bristol Myers Squibb Co | Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek |
| US20020010184A1 (en) * | 2000-02-18 | 2002-01-24 | Dinsmore Christopher J. | Inhibitors of prenyl-protein transferase |
| US20020052380A1 (en) * | 2000-02-18 | 2002-05-02 | Dinsmore Christopher J. | Inhibitors of prenyl-protein transferase |
| US6384031B2 (en) * | 2000-03-13 | 2002-05-07 | Ortho-Mcneil Pharmaceutical, Inc. | Cyclobutene derivatives useful as antagonists of the motilin receptor |
| WO2001068621A1 (en) * | 2000-03-13 | 2001-09-20 | Ortho-Mcneil Pharmaceutical, Inc. | Novel cyclohexene derivatives useful as antagonists of the motilin receptor |
| AU2001249144A1 (en) * | 2000-03-13 | 2001-09-24 | Ortho-Mcneil Pharmaceutical, Inc. | Novel cyclopentene derivatives useful as antagonists of the motilin receptor |
| US6511980B2 (en) * | 2000-05-05 | 2003-01-28 | Ortho Mcneil Pharmaceutical, Inc. | Substituted diamine derivatives useful as motilin antagonists |
| GB0013378D0 (en) * | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Use of therapeutic benzamide derivatives |
| US7102009B2 (en) * | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US7105682B2 (en) * | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US6878714B2 (en) * | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| DE50204789D1 (de) | 2001-05-10 | 2005-12-08 | Solvay Pharm Gmbh | Neue 1-amidomethylcarbonyl-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| US6977264B2 (en) * | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
| GB0129015D0 (en) * | 2001-12-04 | 2002-01-23 | Glaxo Group Ltd | Compounds |
| GB0129013D0 (en) * | 2001-12-04 | 2002-01-23 | Glaxo Group Ltd | Compounds |
| SE0203302D0 (sv) * | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Compounds |
| US7223788B2 (en) * | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
| US7262195B2 (en) | 2003-09-17 | 2007-08-28 | Bristol-Myers Squibb Company | Compounds useful as motilin agonists and method |
| US7338954B2 (en) | 2003-09-17 | 2008-03-04 | Bristol-Myers Squibb Company | Compounds useful as motilin agonists and method |
| JP2007508303A (ja) * | 2003-10-01 | 2007-04-05 | ザ プロクター アンド ギャンブル カンパニー | メラニン凝集ホルモン拮抗物質 |
| JPWO2005063720A1 (ja) * | 2003-12-25 | 2007-07-19 | 日本新薬株式会社 | アミド誘導体及び医薬 |
| WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| WO2005077345A1 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
| WO2005077368A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| CA2559285A1 (en) * | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
| SE0401345D0 (sv) | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds: Pyridine as scaffold |
| GB0611907D0 (en) | 2006-06-15 | 2006-07-26 | Glaxo Group Ltd | Compounds |
| EP1902022A1 (en) | 2005-07-12 | 2008-03-26 | Glaxo Group Limited | Piperazine heteroaryl derivates as gpr38 agonists |
| WO2007012479A2 (en) * | 2005-07-26 | 2007-02-01 | Glaxo Group Limited | Benzylpiperazine derivates and their medical use |
| EP2041093B1 (en) * | 2006-06-28 | 2010-04-21 | Glaxo Group Limited | Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases |
-
2007
- 2007-06-26 EP EP07765616A patent/EP2041093B1/en active Active
- 2007-06-26 PE PE2007000819A patent/PE20080345A1/es not_active Application Discontinuation
- 2007-06-26 WO PCT/EP2007/056342 patent/WO2008000729A1/en active Application Filing
- 2007-06-26 PT PT07765616T patent/PT2041093E/pt unknown
- 2007-06-26 EA EA200970065A patent/EA015820B1/ru not_active IP Right Cessation
- 2007-06-26 DE DE602007006019T patent/DE602007006019D1/de active Active
- 2007-06-26 DK DK07765616.3T patent/DK2041093T3/da active
- 2007-06-26 AU AU2007263712A patent/AU2007263712B2/en not_active Ceased
- 2007-06-26 AT AT07765616T patent/ATE465150T1/de active
- 2007-06-26 US US11/768,339 patent/US7700599B2/en not_active Expired - Fee Related
- 2007-06-26 KR KR1020087031612A patent/KR20090031688A/ko not_active Ceased
- 2007-06-26 SI SI200730257T patent/SI2041093T1/sl unknown
- 2007-06-26 JO JO2007261A patent/JO2645B1/en active
- 2007-06-26 NZ NZ573450A patent/NZ573450A/en not_active IP Right Cessation
- 2007-06-26 AR ARP070102835A patent/AR061656A1/es not_active Application Discontinuation
- 2007-06-26 MX MX2009000110A patent/MX2009000110A/es active IP Right Grant
- 2007-06-26 BR BRPI0713443-6A patent/BRPI0713443A2/pt not_active IP Right Cessation
- 2007-06-26 ES ES07765616T patent/ES2344484T3/es active Active
- 2007-06-26 CA CA002655540A patent/CA2655540A1/en not_active Abandoned
- 2007-06-26 PL PL07765616T patent/PL2041093T3/pl unknown
- 2007-06-26 JP JP2009517160A patent/JP5028484B2/ja not_active Expired - Fee Related
- 2007-06-26 TW TW096122969A patent/TWI391386B/zh not_active IP Right Cessation
-
2008
- 2008-12-11 IL IL195900A patent/IL195900A0/en unknown
- 2008-12-11 CR CR10497A patent/CR10497A/es not_active Application Discontinuation
- 2008-12-24 MY MYPI20085319A patent/MY147677A/en unknown
- 2008-12-30 MA MA31526A patent/MA30539B1/fr unknown
-
2009
- 2009-01-16 NO NO20090266A patent/NO20090266L/no not_active Application Discontinuation
- 2009-04-02 US US12/417,176 patent/US8853218B2/en not_active Expired - Fee Related
- 2009-07-22 HK HK09106727.8A patent/HK1127608A1/xx unknown
-
2010
- 2010-05-21 HR HR20100284T patent/HRP20100284T1/hr unknown
- 2010-06-11 CY CY20101100521T patent/CY1110190T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20080345A1 (es) | Derivados de piperazina como agonistas del receptor de gpr38 | |
| PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| PE20090237A1 (es) | Derivados de sulfonamidas como inhibidores de los canales de sodio | |
| PE20091408A1 (es) | Compuestos y composiciones como inhibidores de cinasa | |
| PE20060374A1 (es) | Inhibidores de cinasa heterociclicos fusionados | |
| PE20090709A1 (es) | Compuestos heterociclico de 5 miembros | |
| PE20080890A1 (es) | DERIVADOS DE IMIDAZOLONA E IMIDAZOLIDINONA COMO INHIBIDORES DE LA 11b-HSD1 PARA LA DIABETES | |
| PE20080404A1 (es) | Derivados bencil-amino-piperidina como inhibidores de cetp | |
| PE20070189A1 (es) | COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA | |
| PE20010741A1 (es) | Derivados de piperazina como antagonistas de taquicininas | |
| PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
| PE20110237A1 (es) | Derivados de ciclohexilamida como antagonistas del receptor del factor de liberacion de corticotropina (crf-1) | |
| PE20090617A1 (es) | Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa | |
| PE20121614A1 (es) | Derivados de 6-amino,4-carbonil-pirimidina sustituida como antagonistas del receptor ccr2 | |
| PE20050132A1 (es) | Piperazinas heterociclicas sustituidas | |
| PE20060383A1 (es) | Nuevos derivados amino de urea ciclicos como inhibidores de quinasa | |
| PE20090982A1 (es) | Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp) | |
| PE20121640A1 (es) | Derivados de pirazina como inhibidores de bace | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| PE20070111A1 (es) | Aminopirimidinas como moduladores de quinasas | |
| PE20091656A1 (es) | Compuestos heterociclicos como inhibidores de la cinasa raf | |
| CO5611147A2 (es) | Derivados de nicotinamida utiles como inhibidores p38 | |
| PE20071156A1 (es) | COMPUESTOS DERIVADOS DE 4,5,6,7-TETRAHIDRO-1H-INDAZOL COMO POTENCIADORES DEL RECEPTOR DEL ACIDO a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA) | |
| PE20061297A1 (es) | Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c | |
| PE20090717A1 (es) | Derivados de quinolina como inhibidores de la pi3 quinasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |